English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, October 6, 2022
中国疫苗行业的主要参与者艾美疫苗于香港联合交易所主板挂牌
中國疫苗行業的主要參與者艾美疫苗於香港聯合交易所主板掛牌
AIM Vaccine, a Major Player in the Chinese Vaccine Industry, Successfully Listed on the Main Board of SEHK
Wednesday, October 5, 2022
艾美疫苗公布全球发售结果 每股H股发售股份发售价为16.16港元
艾美疫苗公佈全球發售結果 每股H股發售股份發售價為16.16港元
AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 per H Share
Friday, September 23, 2022
艾美疫苗宣布于港交所主板上市计划
艾美疫苗宣佈於港交所主板上市計劃
AIM Vaccine Announces Proposed Listing on the Main Board of SEHK
Wednesday, January 12, 2022
Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance

Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575